tradingkey.logo

Illumina Inc

ILMN
119.720USD
-13.890-10.40%
Close 02/06, 16:00ETQuotes delayed by 15 min
18.32BMarket Cap
21.83P/E TTM

Illumina Inc

119.720
-13.890-10.40%

More Details of Illumina Inc Company

Illumina, Inc. is engaged in providing sequencing-and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. Its DNA sequencing technology is based on its reversible terminator-based sequencing chemistry, referred to as sequencing by synthesis biochemistry. Its BeadArray technology combines microscopic beads and a substrate in a manufacturing process to produce arrays that can perform many assays simultaneously. Its sequencing applications include whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which can sequence exomes, specific genes, RNA or other genomic regions of interest. Its customers include genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and others.

Illumina Inc Info

Ticker SymbolILMN
Company nameIllumina Inc
IPO dateJun 28, 2000
CEOThaysen (Jacob)
Number of employees8970
Security typeOrdinary Share
Fiscal year-endJun 28
Address5200 Illumina Way
CitySAN DIEGO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92122
Phone18582024500
Websitehttps://www.illumina.com
Ticker SymbolILMN
IPO dateJun 28, 2000
CEOThaysen (Jacob)

Company Executives of Illumina Inc

Name
Name/Position
Position
Shareholding
Change
Mr. Jacob Thaysen, Ph.D.
Mr. Jacob Thaysen, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
23.64K
-1301.00%
Dr. Robert S. (Rob) Epstein, M.D.
Dr. Robert S. (Rob) Epstein, M.D.
Independent Director
Independent Director
22.14K
+3780.00%
Dr. Frances H. Arnold, Ph.D.
Dr. Frances H. Arnold, Ph.D.
Independent Director
Independent Director
21.03K
+3780.00%
Mr. Philip W. (Phil) Schiller
Mr. Philip W. (Phil) Schiller
Independent Director
Independent Director
20.15K
+3780.00%
Ms. Patricia (Pat) Leckman
Ms. Patricia (Pat) Leckman
Chief People Officer
Chief People Officer
18.95K
-296.00%
Dr. Gary S. Guthart, Ph.D.
Dr. Gary S. Guthart, Ph.D.
Independent Director
Independent Director
16.43K
+3780.00%
Dr. Steven (Steve) Barnard, Ph.D.
Dr. Steven (Steve) Barnard, Ph.D.
Chief Technology Officer
Chief Technology Officer
16.32K
-515.00%
Ms. Caroline D. Dorsa
Ms. Caroline D. Dorsa
Independent Director
Independent Director
15.19K
+2710.00%
Ms. Susan E. (Sue) Siegel
Ms. Susan E. (Sue) Siegel
Independent Director
Independent Director
14.46K
+3780.00%
Dr. Scott Gottlieb, M.D.
Dr. Scott Gottlieb, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
12.52K
+500.00%
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Jacob Thaysen, Ph.D.
Mr. Jacob Thaysen, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
23.64K
-1301.00%
Dr. Robert S. (Rob) Epstein, M.D.
Dr. Robert S. (Rob) Epstein, M.D.
Independent Director
Independent Director
22.14K
+3780.00%
Dr. Frances H. Arnold, Ph.D.
Dr. Frances H. Arnold, Ph.D.
Independent Director
Independent Director
21.03K
+3780.00%
Mr. Philip W. (Phil) Schiller
Mr. Philip W. (Phil) Schiller
Independent Director
Independent Director
20.15K
+3780.00%
Ms. Patricia (Pat) Leckman
Ms. Patricia (Pat) Leckman
Chief People Officer
Chief People Officer
18.95K
-296.00%
Dr. Gary S. Guthart, Ph.D.
Dr. Gary S. Guthart, Ph.D.
Independent Director
Independent Director
16.43K
+3780.00%

Revenue Breakdown

Currency: USDUpdated: Tue, Jan 6
Currency: USDUpdated: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
Consumables
816.00M
75.28%
Services and Other revenue
157.00M
14.48%
Instruments
111.00M
10.24%
By RegionUSD
Name
Revenue
Proportion
Americas
612.00M
56.46%
Europe
309.00M
28.51%
Asia, Middle East, and Africa
111.00M
10.24%
Greater China
52.00M
4.80%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Consumables
816.00M
75.28%
Services and Other revenue
157.00M
14.48%
Instruments
111.00M
10.24%

Shareholding Stats

Updated: Sat, Jan 31
Updated: Sat, Jan 31
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Capital World Investors
13.07%
The Vanguard Group, Inc.
9.35%
BlackRock Institutional Trust Company, N.A.
8.60%
State Street Investment Management (US)
3.93%
Sessa Capital
3.07%
Other
61.99%
Shareholders
Shareholders
Proportion
Capital World Investors
13.07%
The Vanguard Group, Inc.
9.35%
BlackRock Institutional Trust Company, N.A.
8.60%
State Street Investment Management (US)
3.93%
Sessa Capital
3.07%
Other
61.99%
Shareholder Types
Shareholders
Proportion
Investment Advisor
58.80%
Investment Advisor/Hedge Fund
26.85%
Hedge Fund
12.33%
Pension Fund
2.96%
Bank and Trust
2.08%
Research Firm
2.01%
Sovereign Wealth Fund
0.27%
Family Office
0.26%
Individual Investor
0.19%

Institutional Shareholding

Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
1861
161.13M
105.45%
-21.15M
2025Q3
1888
158.57M
103.78%
-23.77M
2025Q2
1978
167.87M
109.04%
-18.11M
2025Q1
2072
170.79M
107.89%
-16.32M
2024Q4
2074
166.23M
104.94%
-15.71M
2024Q3
2038
151.41M
95.06%
-11.30M
2024Q2
2033
149.41M
93.80%
-18.06M
2024Q1
2096
153.02M
96.09%
-8.97M
2023Q4
2134
150.48M
94.76%
-5.28M
2023Q3
2162
152.18M
96.14%
-14.52M
View more

Shareholder Activity

Name
Shares Held
Proportion
Change
Chg %
Date
Capital World Investors
19.98M
13.07%
+3.33M
+20.01%
Sep 30, 2025
The Vanguard Group, Inc.
14.55M
9.52%
-527.13K
-3.50%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
13.14M
8.6%
-472.32K
-3.47%
Sep 30, 2025
State Street Investment Management (US)
6.00M
3.93%
+382.52K
+6.81%
Sep 30, 2025
Sessa Capital
4.69M
3.07%
-36.09K
-0.76%
Sep 30, 2025
Loomis, Sayles & Company, L.P.
4.29M
2.81%
+61.90K
+1.46%
Sep 30, 2025
WCM Investment Management
4.18M
2.74%
-244.79K
-5.53%
Sep 30, 2025
Corvex Management LP
3.83M
2.51%
--
--
Sep 30, 2025
AQR Capital Management, LLC
3.40M
2.22%
+102.15K
+3.10%
Sep 30, 2025
Geode Capital Management, L.L.C.
2.74M
1.79%
-130.28K
-4.54%
Sep 30, 2025
View more

Related ETFs

Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Invesco Biotechnology & Genome ETF
6.09%
Global X Genomics & Biotechnology ETF
5.58%
First Trust Nasdaq Lux Digi Health Solutions ETF
4.96%
First Trust NYSE Arca Biotechnology Index Fund
4.42%
ARK Genomic Revolution ETF
4.38%
VanEck Biotech ETF
3.09%
Alger Russell Innovation ETF
2.61%
First Trust NASDAQ Pharmaceuticals ETF
2.39%
iShares Health Innovation Active ETF
2.29%
First Trust Health Care Alphadex Fund
2.27%
View more
Invesco Biotechnology & Genome ETF
Proportion6.09%
Global X Genomics & Biotechnology ETF
Proportion5.58%
First Trust Nasdaq Lux Digi Health Solutions ETF
Proportion4.96%
First Trust NYSE Arca Biotechnology Index Fund
Proportion4.42%
ARK Genomic Revolution ETF
Proportion4.38%
VanEck Biotech ETF
Proportion3.09%
Alger Russell Innovation ETF
Proportion2.61%
First Trust NASDAQ Pharmaceuticals ETF
Proportion2.39%
iShares Health Innovation Active ETF
Proportion2.29%
First Trust Health Care Alphadex Fund
Proportion2.27%

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data

Stock Splits

Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
KeyAI